Search This Blog

Thursday, April 30, 2020

WuXi teams up with Aravive to develop biologics for cancer

WuXi Biologics (OTCPK:WXXWY) inks an agreement with Aravive (NASDAQ:ARAV) aimed at developing high-affinity bispecific antibodies for a target in cancer and fibrosis called CCN2.
Under the terms of the partnership, Aravive will have access to the former’s WuXiBody platform and will be responsible for preclinical and clinical development while WuXi will be responsible for discovery, process development and manufacturing.
Financial terms remain confidential.
https://seekingalpha.com/news/3566839-wuxi-teams-up-aravive-to-develop-biologics-for-cancer

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.